Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03076567 · ClinicalTrials.gov registry record
Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 440
- Enrollment target
NCT03076567: Completed study, sponsored by National Cancer Institute (NCI).
NCT03076567 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 440 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03076567 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 440 participants
- Enrollment target
Study Summary
Background: Stomach cancer is common around the world. The US is a low-risk region. But the 5-year survival rate in the US is low. This is because the cancer is usually in a late stage by the time it is diagnosed. One way to detect it earlier is to screen many people with a procedure called endoscopy. But this may not be feasible in low-risk or developing countries. Researchers want to find a biomarker for early-stage disease to help them create an effective way of screening. DNA methylation is a chemical modification of DNA. It generates a signal for certain cancers, including stomach cancer. Researchers want to find a blood-based DNA methylation marker for stomach cancer. Objective: To study plasma DNA methylation as a potential biomarker for detection of stomach cancer. Eligibility: Participants from 2 studies already done in China Design: Researchers will use blood samples from participants in the 2 studies. The blood was collected in 1999/2000. They will use samples from some who developed stomach cancer between those years and 2006. The other samples will be from some who stayed cancer free in that time. Participants already gave written informed consent. Researchers will take DNA from the samples. They will look for methylation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2020-02-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03076567
The ClinicalTrials.gov registry entry for NCT03076567 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03076567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03076567 about?
NCT03076567 is a clinical study titled "Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer". Background: Stomach cancer is common around the world. The US is a low-risk region. But the 5-year survival rate in the US is low. This is because the cancer is usually in a late stage by the time it is diagnosed. One way to detect it earlier is to screen many people with a procedure called endosco...
What is the current status of trial NCT03076567?
This trial is currently completed. The enrollment target is 440 participants. The study started on 2017-03-09. Estimated completion is 2020-02-21.
Who is sponsoring clinical trial NCT03076567?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.